Patents by Inventor Christian P. Larsen

Christian P. Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10561728
    Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 18, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Keith A. Reimann, Rijian Wang, Christian P. Larsen
  • Publication number: 20180344845
    Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 6, 2018
    Inventors: Keith A. Reimann, Rijian Wang, Christian P. Larsen
  • Patent number: 9987356
    Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: June 5, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Keith A. Reimann, Rijian Wang, Christian P. Larsen
  • Publication number: 20170051059
    Abstract: Methods of treating renal transplant rejection using anti-CD40L domain antibodies are provided. The anti-CD40L dAbs are less likely to cause platelet aggregation and thus cause thromboembolism. Appropriate anti-CD40L dAbs doses and administration regimens are also provided. Combination treatments for transplant rejection, particularly renal transplant rejection, using anti-CD40L dAbs, a CTLA4 mutant molecule (e.g., belatacept) and/or anti-CD28 optionally with conventional immunosuppressive renal transplant therapy are provided.
    Type: Application
    Filed: March 19, 2015
    Publication date: February 23, 2017
    Applicants: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company
    Inventors: Anish SURI, Steven G. NADLER, Christian P. LARSEN, Andrew Briane ADAMS
  • Publication number: 20160324834
    Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 10, 2016
    Inventors: Rafi R. Ahmed, Christian P. Larsen, Koichi Araki
  • Publication number: 20140370059
    Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.
    Type: Application
    Filed: August 25, 2014
    Publication date: December 18, 2014
    Inventors: Rafi R. Ahmed, Christian P. Larsen, Koichi Araki
  • Patent number: 8840899
    Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: September 23, 2014
    Assignee: Emory University
    Inventors: Rafi Ahmed, Christian P. Larsen, Koichi Araki
  • Publication number: 20140093497
    Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
    Type: Application
    Filed: March 12, 2012
    Publication date: April 3, 2014
    Applicants: EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER INC
    Inventors: Keith A. Reimann, Rijian Wang, Christian P. Larsen
  • Publication number: 20110129496
    Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.
    Type: Application
    Filed: August 5, 2009
    Publication date: June 2, 2011
    Applicant: EMORY UNIVERSITY
    Inventors: Rafi Ahmed, Christian P. Larsen, Koichi Araki
  • Patent number: 7829534
    Abstract: The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams, Robert J. Peach, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Publication number: 20090186037
    Abstract: The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
    Type: Application
    Filed: September 10, 2008
    Publication date: July 23, 2009
    Inventors: Christian P. Larsen, Alejandro A. Aruffo, Diane L. Hollenbaugh, Peter S. Linsley, Jeffrey A. Ledbetter, Thomas C. Pearson
  • Publication number: 20080160022
    Abstract: The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 3, 2008
    Applicant: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams, Robert J. Peach, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Patent number: 7304033
    Abstract: The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: December 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams, Robert J. Peach, Peter S. Linsley, Joseph Roy Naemura, Jurgen Bajorath
  • Publication number: 20030022836
    Abstract: The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
    Type: Application
    Filed: May 23, 2002
    Publication date: January 30, 2003
    Inventors: Christian P. Larsen, Thomas C. Pearson, Andrew B. Adams
  • Publication number: 20030007968
    Abstract: Methods of establishing hematopoietic chimerism useful to correct hematological diseases and promote acceptance of organ transplants include administering busulfan, costimulation blockade, and readily attainable numbers of T-cell depleted bone marrow cells.
    Type: Application
    Filed: January 25, 2002
    Publication date: January 9, 2003
    Inventors: Christian P. Larsen, Thomas C. Pearson, Edmund K. Waller, Andrew B. Adams
  • Publication number: 20020031510
    Abstract: The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
    Type: Application
    Filed: May 22, 2001
    Publication date: March 14, 2002
    Applicant: Bristol-Myers Squibb Company
    Inventors: Christian P. Larsen, Alejandro A. Aruffo, Diane L. Hollenbaugh, Peter S. Linsley, Jeffrey A. Ledbetter, Thomas C. Pearson
  • Patent number: 5916560
    Abstract: The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: June 29, 1999
    Assignees: Bristol-Myers Squibb Company, Emory University
    Inventors: Christian P. Larsen, Alejandro A. Aruffo, Diane L. Hollenbaugh, Peter S. Linsley, Jeffrey A. Ledbetter, Thomas C. Pearson